Drug improves cystic fibrosis pulmonary inflammation and protein function [PreClinical]
1. Thymosin α1 (Tα1), an immunomodulatory drug currently in use, decreased lung inflammation in a mouse model of cystic fibrosis ...
1. Thymosin α1 (Tα1), an immunomodulatory drug currently in use, decreased lung inflammation in a mouse model of cystic fibrosis ...
1. After adjusting for risk factors associated with survival, Canadian patients had a median age of survival that was 10 ...
1. In patients with cystic fibrosis, monthly use of non-viral pGM169/GL67A gene therapy was associated with a significant, but modest, ...
1. Mucus from cystic fibrosis patients had a rope-like structure and high elasticity due to chemical cross-links between mucin proteins. ...
Originally published by Harvard Health. What Is It? Cystic fibrosis is an inherited disease. It causes cells to produce mucus ...
1. From 2000 to 2010, adjusted mortality for cystic fibrosis (CF) patients dropped by 17% (1.8% per year). 2. Median ...
Image: PD 1. Among infants randomized to undergo either newborn screen with cystic fibrosis (CF) testing included or undergo normal ...
Image: PD 1. Neutrophil elastase activity in bronchoalveolar lavage fluid at 3 months is a risk factor for persistent bronchiectasis ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.